The surprising role fibrinogen plays in regulating the body's response to disease

(University of Alberta Faculty of Medicine&Dentistry) A finding from University of Alberta researchers is shining new light on the role fibrinogen has in regulating a natural defence mechanism in the body. The discovery is hoped to contribute to improved diagnosis and treatments for patients in a variety of diseases ranging from inflammation, to heart failure, to cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

By KIP SULLIVAN, JD The Medicare Payment Advisory Commission (MedPAC) and other proponents of the Hospital Readmissions Reduction Program (HRRP) justified their support for the HRRP with the claim that research had already demonstrated how hospitals could reduce readmissions for all Medicare fee-for-service patients, not just for groups of carefully selected patients. In this three-part series, I am reviewing the evidence for that claim. We saw in Part I and Part II that the research MedPAC cited in its 2007 report to Congress (the report Congress relied on in authorizing the HRRP) contained no studies supporting tha...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Policy Medicare health reform Hospital Readmissions Reduction Program HRRP Kip Sullivan MedPAC Source Type: blogs
ConclusionOne year of trastuzumab increases the risk of cardiac events, though most consist of asymptomatic or mildly symptomatic LVEF drops. Adjuvant trastuzumab should be considered a safe treatment from a cardiac standpoint for most patients. Trastuzumab-associated cardiotoxicity is the main cause of discontinuation and further research is needed to individualize prevention and management.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
This study evaluated the impact of pharmacy-led HF TOC on HF readmission rate. Methods: This was a single-center, pre-post quasi-experimental study. Pharmacy TOC comprised admission and discharge medication reconciliations and patient education. Patients were included if they had a primary HF diagnosis. Patients were excluded if they were admitted for a non-HF diagnosis, admitted for
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Tags: Ann Pharmacother Source Type: research
Two Americans and a Briton won the 2019 Nobel Medicine Prize on Monday for discovering a molecular switch that regulates how cells adapt to fluctuating oxygen levels, opening up new approaches to treating heart failure, anaemia and cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Fitbit or Apple Watch for running? Garmin or Misfit for swimming? Sleep Cycle or Sleep as Android for sleep tracking? What about measuring heart rate, blood pressure, or tracking how to cut out stress from your life? Dozens of gadgets on the healthcare wearable market promise you a healthier lifestyle, but it’s easy to go astray in the jungle of digital health gadgets. Let me show you my top choices when it comes to health wearables and trackers. Guidance in the health wearable universe By now, I have tested and used more than a hundred devices and gadgets that measure health parameters or vital signs. Thus,...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Health Sensors & Trackers Portable Diagnostics activity fitness fitness trackers Health 2.0 Healthcare Innovation meditation mental health Personalized medicine sleep sleep optimization sleep tracking stress technology wear Source Type: blogs
Left ventricular systolic dysfunction (LVSD) and overt heart failure are well known manifestations of chemotherapy-induced cardiotoxicity. The development of LVSD is clinically significant because it can impact the delivery of lifesaving chemotherapy and increase the risk of developing heart failure, compromising quality of life and survival years after cure of the cancer. Cancer treatment –related cardiomyopathy is most commonly associated with anthracyclines and trastuzumab. Several interventions have been identified to prevent cancer-induced cardiomyopathy. Anthracyclines is a major culprit, and prevention strateg...
Source: Cardiology Clinics - Category: Cardiology Authors: Source Type: research
Novel pharmacological therapies are in development for cancer, ranging from conventional chemotherapeutic drugs to molecular targeted drugs, antibody-based drugs, and immune checkpoint inhibitors, which are developed using new technologies. However, the increasing cost of new drug development is increasing the costs of national healthcare and putting pressure on government finances worldwide. Under these circumstances, drug repositioning (i.e. discovering novel effects of existing drugs, thereby allowing their use to treat other diseases) has become a major focus because of reliability and cost reduction. It is becoming in...
Source: European Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Review Article: Lifestyle Source Type: research
CONCLUSION: We identified clinical predictors or determinants of dyspnea that have pathophysiological bases. Dyspnea was independently associated with functional EC. These results have implications in efforts to reduce dyspnea and improve exercise behavior and functional EC in lung cancer survivors following curative-intent therapy. PMID: 31592931 [PubMed - as supplied by publisher]
Source: Journal of Cardiopulmonary Rehabilitation and Prevention - Category: Rehabilitation Authors: Tags: J Cardiopulm Rehabil Prev Source Type: research
ConclusionsA high incidence of CV events, with no apparent correlation with CV comorbidities or risk factors, was observed. Prompt identification and treatment of CV events allowed most pts to complete the treatment with FP.Clinical trial identificationNCT02665312.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureM. Aglietta: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Merck; Advisory / Consultancy: Roche. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsDiabetes and NT-proBNP values seem to be associated with an increased risk of cardiotoxicity in breast cancer patients during trastuzumab treatment. In diabetics, glycaemic control and a more intense cardiac monitoring could provide objective benefits during the treatment. Moreover, NT-proBNP determination could become an accessible way to evaluate cardiac risk in this context.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Dentistry | Heart | Heart Failure